Refanalin

N/A

Report date: 2024/11/24 20:00:04
NME

Base Information

Drug NameRefanalin
Drug Alias NameANG-3777BB-3SNV-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor agonists
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Delayed Graft FunctionMyocardial Infarction +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesElicio TherapeuticsVifor Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElicio TherapeuticsVifor Pharma
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Delayed Graft FunctionMyocardial Infarction +[5] 

Other Information

ATC CodeN/A
Related LinksN/A